Dendreon Corporation  

(Public, OTCMKTS:DNDNQ)   Watch this stock  
Find more results for NASDAQ:DNDN
-0.009 (-5.70%)
Nov 21 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.14 - 0.17
52 week 0.10 - 3.52
Open 0.16
Vol / Avg. 6.62M/8.70M
Mkt cap 23.83M
P/E     -
Div/yield     -
EPS -1.06
Shares 158.72M
Beta 2.48
Inst. own 33%
Nov 10, 2014
Q3 2014 Dendreon Corp Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -30.18% -104.60%
Operating margin -11.93% -85.65%
EBITD margin - -54.78%
Return on average assets -25.12% -51.37%
Return on average equity - -
Employees 755 -
CDP Score - -


SUITE 3200, 1301 2ND AVE.
United States - Map
+1-206-2197815 (Phone)
+1-206-2560571 (Fax)

Website links


Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may significantly improve cancer treatment options for patients. The Company's product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating multiple types of cancers. PROVENGE (sipuleucel-T), is the Company's first commercialized product approved by the United States Food and Drug Administration (FDA), and is a autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, castrate-resistant (hormone-refractory) prostate cancer. The Company owns worldwide rights for PROVENGE. Other product candidates the Company has under development include its investigational active cellular immunotherapy, DN24-02. The Company completed its Phase I clinical trial in April 2012 to evaluate Transient Receptor Potential, sub-family M (TRPM8).